Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 12,34 € (+80,15 %). Medianen er 13,65 € (+99,27 %).
| Køb |
15 |
| Behold |
6 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Iovance Biotherapeutics raises annual guidance after strong demand for Amtagvi and Proleukin
Strong market demand for the cancer therapies Amtagvi (Lifileucel) and Proleukin has led Iovance Biotherapeutics to significantly raise its annual forecast. The company is expanding its TIL therapy platform and broadening the clinical pipeline for additional solid tumors. Despite a weak overall market, investors are drawing the stock higher, signaling company-specific momentum. » Mere på finanzen.net
Iovance raises 2026 revenue forecast after strong demand for Amtagvi
Iovance raised its 2026 revenue forecast to $410–420 million, supported by rising U.S. demand for Amtagvi and Proleukin. Shorter production times and more than 110 treatment centers are driving growth and pushed the stock up about 10% to a 52-week high. The business remains based on tumor-infiltrating lymphocytes (TIL), which are increasingly entering clinical practice for solid tumors. » Mere på finanzen.net
Iovance Biotherapeutics accelerates revenue growth after successful launch of Amtagvi
Iovance Biotherapeutics is commercializing Amtagvi, the world’s first approved personalized TIL cell therapy for advanced melanoma. Rapid onboarding of specialized treatment centers and rising patient demand are driving dynamic revenue acceleration in the current fiscal year. Analysts view the first-mover advantage and the successful market entry as drivers for further operational growth. » Mere på finanzen.net
Iovance Biotherapeutics reaches 52-week high at $9.36
Iovance Biotherapeutics shares rose to a 52-week high of $9.36, delivering a year-to-date return of 215% and nearly a 279% gain over the past year; market capitalization is around $4.2 billion. In Q2 2026 the company reported record revenue of $99.31 million, driven by strong sales of the cancer therapy Amtagvi ($91 million), and an adjusted loss of $0.11 per share, beating expectations. UBS raised its price target to $7.00 (rating: neutral), TD Cowen increased its target to $10.00 and maintained buy; InvestingPro currently considers the stock overvalued. » Mere på de.investing.com
Iovance reports record Q2 revenue and reviews 2026 guidance on strong Amtagvi demand
Iovance reported record Q2 revenue of about $99.3 million, a 66% year-over-year increase driven by strong Amtagvi sales (U.S. Amtagvi ~$91M) and Proleukin ~$9M. Gross margin improved to 56% on higher volumes, manufacturing efficiencies and cost optimisation, while R&D expenses fell for a fourth consecutive quarter. Management is reviewing its 2026 revenue guidance of $350–370 million with an updated outlook expected in Q3, and continues expanding its treatment network to over 95 centres (forecasting at least 110 by year-end). The company finished the quarter with roughly $304 million in cash and is advancing multiple late‑stage clinical programmes and international regulatory submissions. » Mere på finance.yahoo.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 107,24 mio. | 86,57 % |
| Bruttofortjeneste | 64,84 mio. | 162,57 % |
| Nettoresultat | -19,66 mio. | 74,71 % |
| EBITDA | -10,74 mio. | 83,90 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 3,14 mia. € |
Antal aktier | 462,66 mio. |
Højeste/laveste i 52 uger | 13,98 € - 1,89 € |
| Udbytte | Nej |
Beta | 0,76 |
P/E (PE Ratio) | -14,08 |
PEG (PEG Ratio) | -0,15 |
K/I (PB Ratio) | 4,19 |
P/S (PS Ratio) | 9,11 |
Virksomhedsprofil
Iovance Biotherapeutics, Inc., et klinisk fase biotekselskab, fokuserer på at udvikle og kommercialisere kræftimmunterapiprodukter for at udnytte kraften i en patients immunsystem til at udrydde kræftceller. Selskabet har seks igangværende fase 2-kliniske studier, herunder C-144-01 af dets førende produktkandidat, lifileucel, til behandling af metastatisk melanom; C-145-04 af produktkandidaten lifileucel til tilbagevendende, metastatisk eller vedvarende livmoderhalskræft; og C-145-03 af produktkandidaten LN-145 til tilbagevendende og/eller metastatisk planocellulært karcinom i hoved-hals-området. Iovance Biotherapeutics, Inc. har samarbejder og licensaftaler med H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montréal; Cellectis S.A.; og Novartis Pharma AG. Selskabet var tidligere kendt som Lion Biotechnologies, Inc. og ændrede navn til Iovance Biotherapeutics, Inc. i juni 2017. Iovance Biotherapeutics, Inc. blev stiftet i 2007 og har hovedkvarter i San Carlos, Californien.
| Navn | Iovance Biotherapeutics |
| CEO | Frederick G. Vogt |
| Hjemsted | San Carlos,
ca USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 15.10.2010 |
| Medarbejdere | 975 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | IOVA |
London Stock Exchange | 0JDK.L |
Frankfurt | 2LB.F |
Düsseldorf | 2LB.DU |
London | 0JDK.L |
München | 2LB.MU |